Latest Pharmaceutical drug Stories
Connie K. Ho for redOrbit.com – Your Universe Online New Delhi-based Ranbaxy Laboratories recently announced that they would stop production of Atorvastatin, a product similar to Pfizer Inc.’s Lipitor that focuses on fighting high cholesterol. The company’s decision was prompted by a recent recall by the U.S. Food and Drug Administration (FDA). The voluntary recall covers Atorvastatin tablets at 10mg, 20mg, and 40mg strengths. The tablets were recalled due to the possibility of...
DALLAS, November 30, 2012 /PRNewswire/ -- RnRMarketResearch.com adds new market research report "2012 Deep Research Report on Global and China Synthesis Polypeptide Drug Industry" to its store. 2012 Deep Research Report on Global and China Synthesis Polypeptide Drug Industry is a professional and in-depth research report on China Synthesis Polypeptide Drug market. The report introduces Synthesis Polypeptide Drug with basic information including definition,...
ST. LOUIS, Nov. 28, 2012 /PRNewswire/ -- Price inflation of branded pharmaceutical drugs is far outpacing overall economic inflation, according to new data released today by Express Scripts (NASDAQ: ESRX). (Logo: http://photos.prnewswire.com/prnh/20080827/EXPRESSSCRIPTSLOGO) The Express Scripts 2012 Q3 Drug Trend Quarterly reviews year-to-date and quarter-over-quarter changes in national drug spending for all major therapy classes. The report is the first publication to...
PARSIPPANY, N.J., Nov. 27, 2012 /PRNewswire/ -- With vigorous 15% growth over the previous year and a confluence of factors encouraging even greater growth, the Chinese OTC market provides ample opportunities for OTC marketers. An aging population and increasing incidence of several chronic diseases makes several therapeutic classes appealing for future Rx-to-OTC switches in China, reveals recently published Emerging Markets Rx-to-OTC Switch: Forecasts and Opportunities report...
BOONTON, N.J. and CAMBRIDGE, Mass., Nov. 27, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) and Tarix Pharmaceuticals today announced that the companies have entered into a definitive licensing agreement to develop an oral formulation of TXA127, Tarix's lead peptide drug candidate. The oral formulation of TXA127 is being developed jointly by Unigene and Tarix under a previously agreed upon feasibility program whereby the companies leveraged Unigene's...
WASHINGTON, Nov. 27, 2012 /PRNewswire-USNewswire/ -- The not-for-profit Center for Lawful Access and Abuse Deterrence (CLAAD) today announced that it has selected Pisgah Laboratories' abuse-deterrent technology platform as one of its Top 5 Technologies To Reduce Prescription Drug Abuse. Pisgah Laboratories' lead abuse-deterrent technology product candidate Hydrocodone/APAP, is intended to provide relief to patients in need of treatment, yet lessen the potential for drug abuse....
WASHINGTON, Nov. 27, 2012 /PRNewswire-USNewswire/ -- The not-for-profit Center for Lawful Access and Abuse Deterrence (CLAAD) today recognized Egalet Ltd., a specialty pharmaceutical company focused on developing safe, effective, and tamper-resistant medications, as a Top Five Technologies To Reduce Prescription Drug Abuse honoree. Egalet is developing a pipeline of tamper-resistant opioids that are nearing pivotal testing. Roland Gerritsen van der Hoop, Chief Medical Officer of...
WASHINGTON, Nov. 27, 2012 /PRNewswire-USNewswire/ -- At today's National Prescription Drug Abuse Prevention Policy Consensus Meeting, the not-for-profit Center for Lawful Access and Abuse Deterrence (CLAAD) announced the results of its national contest to identify the "Top 5 Technologies To Reduce Prescription Drug Abuse." In alphabetical order, the Top 5 honorees are ... Atlantic Pharmaceuticals' SMART/Script dosage form to decrease medication tampering; Eagle Advancement...
WASHINGTON, Nov. 27, 2012 /PRNewswire-USNewswire/ -- The Center for Lawful Access and Abuse Deterrence (CLAAD) today honored Atlantic Pharmaceuticals' SMART/Script as one of its "Top 5 Technologies To Reduce Prescription Drug Abuse." Still in investigational stages, the SMART/Script technology is intended to deliver immediate- and extended-release opioid medications in a tamper-resistant form. If a medication formulated with SMART/Script were crushed or chewed, the SMART/Script...
Connie K. Ho for redOrbit.com – Your Universe Online A new study published in the Canadian Medical Association Journal shows that, while there is a rise in the number of prescription drugs that result in negative effects due to interactions with grapefruit, few physicians are aware of these consequences. The article was completed by a group of researchers who discovered the interactions among grapefruit and prescription drugs over 20 years ago. By summarizing the evidence available,...
